İntrakraniyal Kanaması Olan Hastalarda Antitrombotik İlaçların Etkisinin Tersine Çevrilmesi
Özet
Antitrombotik ilaçlar pıhtı oluşumunu önlemede hayati öneme sahip olsa da intrakraniyal kanama (İKK) riskini artırarak klinik tabloları kötüleştirebilmektedir. Semptomatik akut İKK durumlarında, hematomun büyümesini engellemek amacıyla antitrombotik tedavinin derhal kesilmesi ve acil klinik kanıtlar doğrultusunda tersine çevirme (antidot) tedavisine başlanması kritik önem taşır. İlk 24 saatteki hematom genişlemesi mortalite ile doğrudan ilişkili olduğundan, kan basıncının kontrolü (sistolik KB <140-160 mmHg) ve genel destekleyici bakımların hızla uygulanması gerekir. K vitamini antagonistlerine (Varfarin) bağlı kanamalarda 4-faktörlü protrombin kompleks konsantresi (PCC) ve IV K vitamini öncelikli tercihtir. Yeni nesil oral antikoagülanlardan Faktör Xa inhibitörleri için Andeksanet Alfa veya PCC kullanılırken, direkt trombin inhibitörü Dabigatran için spesifik bir monoklonal antikor olan İdarucizumab tercih edilmektedir. Heparin türevlerinde Protamin Sülfat etkilidir; ancak trombolitik ilişkili kanamalarda Kriyopresipitat, cerrahi planlanmayan antiplatelet kaynaklı kanamalarda ise rutin trombosit transfüzyonundan kaçınılması önerilmektedir. Sonuç olarak, koagülopatinin hastaya özgü doğru ajanlarla erken dönemde tersine çevrilmesi, nörolojik hasarı sınırlayarak sağkalım oranlarını anlamlı ölçüde iyileştirir.
Although antithrombotic medications are vital for preventing thrombosis, they substantially increase the risk of intracranial hemorrhage (ICH) and exacerbate clinical outcomes. In symptomatic acute ICH, prompt discontinuation of antithrombotic therapy and rapid initiation of reversal strategies based on clinical evidence are paramount to prevent hematoma expansion. Since early hematoma growth within the first 24 hours directly correlates with increased mortality, immediate blood pressure control (systolic BP <140-160 mmHg) and supportive intensive care are essential. For vitamin K antagonist (Warfarin) induced bleeding, 4-factor prothrombin complex concentrate (PCC) combined with IV vitamin K is the first-line treatment. For direct oral anticoagulants, Andexanet Alfa or PCC is utilized for Factor Xa inhibitors, whereas Idarucizumab, a specific monoclonal antibody, is preferred for the direct thrombin inhibitor Dabigatran. Protamine Sulfate reverses heparin derivatives efficiently, while Cryoprecipitate is indicated for thrombolytic-induced bleeding. Notably, prophylactic platelet transfusion should be avoided in antiplatelet-associated ICH unless emergency surgery is planned. Ultimately, timely, agent-specific reversal of coagulopathy successfully limits secondary neurological deterioration and significantly optimizes survival rates.
Referanslar
Christensen MA, Cooper CM. Developing Guidelines for the Reversal of Anticoagulant and Antithrombotic Agents in the Setting of Intracranial Hemorrhage. Journal of Neuroscience Nursing. 2016;48(5): 256–259. doi:10.1097/JNN.0000000000000210
Le Roux P, Pollack CV Jr, Milan M, et al. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. Journal of Neurosurgery. 2014;121 Suppl: 1–20. doi:10.3171/2014.8.paradigm
Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Archives of Internal Medicine. 2004;164(8): 880–884. doi:10.1001/archinte.164.8.880
Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6): 1059–1064. doi:10.1212/01.wnl.0000138428.40673.83
Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68(2): 116–121. doi:10.1212/01.wnl.0000250340.05202.8b
An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. Journal of Stroke. 2017;19(1): 3–10. doi:10.5853/jos.2016.00864
Bower MM, Sweidan AJ, Shafie M, et al. Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage. Stroke. 2019;50(2): 529–536. doi:10.1161/STROKEAHA.118.023840
Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1): 1–5. doi:10.1161/01.str.28.1.1
Divani AA, Liu X, Di Napoli M, et al. Blood Pressure Variability Predicts Poor In-Hospital Outcome in Spontaneous Intracerebral Hemorrhage. Stroke. 2019;50(8): 2023–2029. doi:10.1161/STROKEAHA.119.025514
Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. The Journal of the American Medical Association. 2015;313(8): 824–836. doi:10.1001/jama.2015.0846
Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022;53(7): e282–e361. doi:10.1161/STR.0000000000000407
Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology. 2009;145(1): 24–33. doi:10.1111/j.1365-2141.2009.07600.x
Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocritical Care. 2016;24(1): 6–46. doi:10.1007/s12028-015-0222-x
Yasaka M, Sakata T, Minematsu K, et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thrombosis Research. 2002;108(1): 25–30. doi:10.1016/s0049-3848(02)00402-4
Australian Product Information. XARELTO® (rivaroxaban). (12/08/2022 tarihinde https://resources.bayer.com.au/resources/uploads/PI/file9466.pdf adresinden ulaşılmıştır).
Bristol Myers Squibb. ELIQUIS® (apixaban). (12/08/2022 tarihinde https://packageinserts.bms.com/pi/pi_eliquis.pdf adresinden ulaşılmıştır).
Momin JH, Candidate P, Hughes GJ. Andeksanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants. Pharmacy and Therapeutics. 2019;44(9): 530–549.
Panos NG, Cook AM, John S, et al. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation. 2020;141(21): 1681–1689. doi:10.1161/CIRCULATIONAHA.120.045769
Cohen AT, Lewis M, Connor A, et al. Thirty-day mortality with andeksanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. Journal of the American College of Emergency Physicians Open. 2022;3(2): e12655. doi:10.1002/emp2.12655
Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol 2019;94(6):697–709. doi: 10.1002/ajh.25475.
Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. The New England Journal of Medicine. 2015;373(6): 511–520. doi:10.1056/NEJMoa1502000
Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andeksanet Alfa for Bleeding Associated with Factor Xa Inhibitors. The New England Journal of Medicine. 2019;380(14): 1326–1335. doi:10.1056/NEJMoa1814051
Elmer J, Wittels KA. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfusion Medicine. 2012;22(2): 108–115. doi:10.1111/j.1365-3148.2011.01125.x
Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine. 2013;19(4): 446–451. doi:10.1038/nm.3102
Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038): 2605–2613. doi:10.1016/S0140-6736(16)
